Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade

1. Boehringer Ingelheim is focusing on their late-stage pipeline to plan for 25 new product launches over the next decade.
2. Jardiance, a drug for Type 2 diabetes and heart failure, has seen significant sales growth due to expanded indications, generating 5.8 billion euros in 2022.
3. Jardiance has shown success in the EMPA-KIDNEY study, leading to applications for approval in the United States and Europe for treating chronic kidney disease.
4. The company has also made a push into contract manufacturing, generating 1 billion euros in CDMO revenue in 2022.
5. Boehringer Ingelheim has undergone a management reshuffle, with Allan Hillgrove retiring and Carine Brouillon taking his place on the board and as head of the pharma division.
6. The company has made recent acquisitions to expand its pipeline, including Amal Therapeutics for cancer vaccines and Yuhan for a NASH candidate.
7. Boehringer Ingelheim reported having about 90 development projects in human pharmaceuticals, with 71% having therapeutic breakthrough potential and 63% having the potential to be first substance in a new class of active ingredient.